We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
-10.91%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$820M
AUM Growth
-$259M
Cap. Flow
-$21.2M
Cap. Flow %
-2.59%
Top 10 Hldgs %
98.94%
Holding
14
New
–
Increased
–
Reduced
4
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$12.7M
2
THRD
Third Harmonic Bio
THRD
+$6.3M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$2.11M
4
SPRO icon
Spero Therapeutics
SPRO
+$116K
5
DYN icon
Dyne Therapeutics
DYN
+$23.1K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$8.51B
$197M 24.03%
4,896,462
– –
DYN icon
2
Dyne Therapeutics
DYN
$4.7B
$189M 23.05%
8,019,354
-782
-0% -$23.1K
IRON icon
3
Disc Medicine
IRON
$2.96B
$159M 19.41%
2,509,456
– –
THRD
4
DELISTED
Third Harmonic Bio
THRD
$107M 13.06%
10,402,286
-505,573
-5% -$6.3M
DAWN
5
DELISTED
Day One Biopharmaceuticals
DAWN
$81.5M 9.94%
6,430,257
– –
KRRO icon
6
Korro Bio
KRRO
$150M
$43.3M 5.28%
1,137,149
– –
VIGL
7
DELISTED
Vigil Neuroscience
VIGL
$9.92M 1.21%
5,836,874
– –
GBIO
8
DELISTED
Generation Bio
GBIO
$8.78M 1.07%
827,948
– –
IMA
9
ImageneBio Inc
IMA
$63M
$8.23M 1%
418,182
– –
QTTB icon
10
Q32 Bio
QTTB
$466M
$7.2M 0.88%
2,092,106
– –
JBIO
11
Jade Biosciences
JBIO
$1.2B
$4.77M 0.58%
51,407
– –
TECX
12
Tectonic Therapeutic
TECX
$529M
$3.62M 0.44%
78,447
-300,000
-79% -$12.7M
SPRO icon
13
Spero Therapeutics
SPRO
$67.7M
$314K 0.04%
305,255
-97,630
-24% -$116K
DNTH icon
14
Dianthus Therapeutics
DNTH
$5.84B
– –
-76,979
Closed -$2.11M

Similar funds

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AT
Avenir Tech Hong Kong $790M AUM 17.91% 1-Year Est. Return
MTWSIF
Mivtachim The Workers Social Insurance Fund Tel Aviv, Israel $789M AUM 73.25% 1-Year Est. Return
VH
V3 Holding Rye, New York $789M AUM 459.57% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return
VCM
Vision Capital Management Portland, Oregon $792M AUM 18.17% 1-Year Est. Return
SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Atlas Venture Life Science Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Atlas Venture Life Science Advisors held 14 positions worth $820M, down 24% from $1.08B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Atlas Venture Life Science Advisors's Q4 2024 filing shows 4 reduced and 1 closed positions. The largest sale was Tectonic Therapeutic, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors's biggest Q4 2024 reduction was Tectonic Therapeutic, cutting an estimated $12.7M.
  • Atlas Venture Life Science Advisors fully exited Dianthus Therapeutics in Q4 2024, selling an estimated $2.11M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 99% of its $820M portfolio in Q4 2024.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q4 2024.
  • Atlas Venture Life Science Advisors's portfolio value fell 24% quarter-over-quarter to $820M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.